Pharma Mar SA · BME:PHM
Pharma Mar SA — Investor Presentation (October 2016)
32 slides from Pharma Mar SA's investor presentation, October 2016
Slide 1: Corporate Presentation October 2016
CORPORATE PRESENTATION October 2016
Slide 2: Disclaimer
Disclaimer This document includes only summary information is not intended to be comprehensive. This document includes "forward-looking statements" that are based on Management’s current expectations. Factors that could cause future results to differ materially from such expectations include, but ar
Slide 3: Investment Highlights
Investment Highlights A leader in the development & commercialization of marine-derived oncology drugs Multinational biotechnology company developing marine-derived oncology drugs Fully integrated biotechnology company – from discovery to commercialization Highly productive R&D organization (1
Slide 4: Unique R&D platform
Unique R&D platform Continuously building the pipeline Fully integrated drug development capabilities Marine expeditions Sample library Screening & Synthesis Clinical Trials Commercialization Marine derived New drug Patent Pre-clinical Oncology-focused sales force products candidates prote
Slide 5: The Plan for Growth
The Plan for Growth Potential to commercialize new oncology products in more indications PharmaMar in the near future PharmaMar • 3 marketed tomorrow products PharmaMar • 2 marketed • ≥ 5 indications today products • 3 indications • 1 marketed product PM1183 • 2 indications Small Cell Lung Apl
Slide 6: A Balanced portfolio of product candidates
A Balanced portfolio of product candidates Overview Registration Clinical Program / Indication Phase I Phase II Phase III Application Market Partners Yondelis® Soft Tissue Sarcoma 2nd/3rd line; EU/others Single agent Ovarian Cancer 2nd/3rd line; EU/others (Yondelis®+Doxil) Soft Tissue Sarcoma 2nd/3r
Slide 7: Innovative Strategy in Oncology
Innovative Strategy in Oncology Novel Chemical entities Novel mechanism of action TS 3’ RNA 5’ RNA pol II 5’ 3’ Yondelis NTS Yondelis and PM1183 inhibits RNA pol II Aplidin binds to eEF1A2 7
Slide 8: Pipeline – PM1183
Pipeline – PM1183 Transcription addiction as a target in cancer Cancer cells aberrantly deregulate specific gene expression programs with critical functions in cell differentiation, proliferation and survival (Hoadley et al 2014) These altered gene programs in cancer cells have a striking depend
Slide 9: PM1183: Key oncology compound – accelerating growth
PM1183: Key oncology compound – accelerating growth PM1183, a second generation Yondelis®, with activity in new indications. YONDELIS® PM1183 HO MeO OCH3 OPTIMIZATION NH MeO IMPROVED PK PROFILE O HO NH OCH3 N H AcO S O HO O H AcO S N O H N N O N O O OH O OH PM1183 is administered as a 1h infusion
Slide 10: Pipeline – PM1183
Pipeline – PM1183 Key oncology compound – accelerating growth • Blockade of trans-activated transcription but not of basal transcription. • Induction of the degradation of RNA Pol II but not of RNA Pol I nor of RNA Pol III. RNA POL II BLOCKADE RNA POL II DEGRADATION* P CDK7 P CDK9 RNAPII P P P PM118
Slide 11: PM1183: Marked effect on tumor microenvironment
PM1183: Marked effect on tumor microenvironment Marked effect on tumor microenvironment by inhibiting transcription of selected cytokines (VEGF, CCL2, IL6, IL8, PTX3) in Tumor-Associeated Macrophages. Tumor-Associated Macrophages (TAMs) elicit cancer-promoting inflammation implicated in: PM1183
Slide 12: Pipeline – PM1183 Development strategy
Pipeline – PM1183 Development strategy CLINICAL PROGRAM/ REGISTRATION INDICATION PHASE I PHASE II PHASE III APPLICATION MARKET PARTNERS PM1183® Plat. Resistant ovarian cancer Single agent 2nd/3rd line SCLC 1183 + Doxorrubicin 2nd/3rd line BRCA 1/2 Breast cancer Single agent 2nd/3rd line Basket Trial
Slide 13: PM1183 – Phase II Small Cell Lung Cancer
PM1183 – Phase II Small Cell Lung Cancer Trial results – Active treatment as second-line therapy with Doxo Best RECIST v.1.1 overall response during treatment (n=21) PM01183 + DOX Kaplan-Meier global PFS and according to CTFI (n=21) (2nd line cohort) 1.0 RR: 67 % 0.9 Cumulative probability (95%CI: 4
Slide 14: PM1183 – Phase II Small Cell Lung Cancer
PM1183 – Phase II Small Cell Lung Cancer Trial results – Active treatment as second-line therapy with Doxo Waterfall plot SCLC 2nd line (COHORT A), showing Best RECIST v.1.1 response according to CTFI maximal tumor variation in size according to CTFI (n=21). N 100 Increase (%) 90 12 80 70 60 * 10 18
Slide 15: PM1183 – Phase III Small Cell Lung Cancer
PM1183 – Phase III Small Cell Lung Cancer SCLC Trial Design • Primary endpoint: median PFS ─ HR≤ 0.7 in PFS with 90% power; ─ Futility analysis planned at n=150 approximately • Key secondary endpoints: ─ OS (If improvement from 8 to 9,5 months occurs, there is 75% chance to detect a trend towards st
Slide 16: PM1183 – Small Cell Lung Cancer
PM1183 – Small Cell Lung Cancer Market overview In the US per annum: In EU-28 per annum: ~ 221,200 new cases of lung cancer ~ 312,645 new cases of lung cancer ~158,040 deaths from lung cancer (=~ 27% of ~267,700 deaths from lung cancer in 2012 all cancer deaths) More die of lung cancer tha
Slide 17: PM1183 – Phase III Platinum Resistant Ovarian Cancer
PM1183 – Phase III Platinum Resistant Ovarian Cancer ROC Trial Design Phase III ROC 420 Patients Randomization 1:1 Stratified by: ECOG PS (0 vs. ≥1 PFI (1-3 vs. > 3mths) Prior CT (1-2 vs. 3 lines) Arm B: Arm A: PLD PM1183 (D1 q4wk i.v.) (D1 q3wk i.v.) No Crossover or 3.2mg/m² Topotecan (D1-D
Slide 18: PM1183 – Platinum Resistant Ovarian Cancer
PM1183 – Platinum Resistant Ovarian Cancer Market overview Worldwide, per year: ~ 250,000 new cases of ovarian cancer ~150,000 deaths from ovarian cancer Platinum resistant patients account ~15% of all ovarian cancer patients Among gynecological malignancies, OC is the second most common and
Slide 19: PM1183 – Phase IIb in BRCA 1/2-Associated Breast Cancer
PM1183 – Phase llb in BRCA 1/2-Associated Breast Cancer Trial design Phase llb in BRCA as a single agent Phase II MBC 117 Patients Non (or UKN) BRCA 1 / 2 mutation BRCA 1 / 2 mutation 20 patients Interim analysis 30 patients 53 patients 64 patients Further development if: Further development if: ≥17
Slide 20: PM1183 – Phase IIb in BRCA 1/2-Associated Breast Cancer
PM1183 – Phase llb in BRCA 1/2-Associated Breast Cancer Clinical efficacy: Overall Response Rate (ORR) PM01183 Treatment (n=54) 7 mg FD (n=35) or 3.5 mg/m2 (n=19) 1-h i.v. infusion, q3wk Best Overall Response (RECIST) (n evaluable: 54 pts) ORR (Confirmed Responses) 22 (40.7%) (95%CI) (27.6 - 55.0)
Slide 21: PM1183 – Phase IIb in BRCA 1/2-Associated Breast Cancer
PM1183 – Phase llb in BRCA 1/2-Associated Breast Cancer Best ORR in specific subpopulations Prior Prior BRCA Hormone Status advanced Platinum CT lines Triple No Yes 1 2 HR+ 0-1 2-3 Negative (n: 27) (n: 27) (n: 31) (n: 23) (n: 21*) (n: 31) (n: 23) (n: 33) ORR 56% 26% 26% 61% 36% 48% 52% 26% (95% CI)
Slide 22: PM1183 – Phase IIb in BRCA 1/2-Associated Breast Cancer
PM1183 – Phase llb in BRCA 1/2-Associated Breast Cancer Clinical efficacy: Progression Free Survival (PFS) and Overall Survival OS Median PFS BRCA 1/2: Median OS BRCA 1/2: 4.1 months 95% CI (2.8-5.9) 20.0 months 95% CI (10.9-31.8) BRCA 1: 2.7 95% CI (2.1-4.6) BRCA 1: 11.8 95% CI (6.5-20.0) BRCA 2: 5
Slide 23: PM1183 – BRCA 1/2 and TNBC Breast Cancer
PM1183 – BRCA 1/2 and TNBC Breast Cancer Market overview Market opportunity: ~ 229,000 new cases of breast cancer in the US and ~367,090 new cases in the EU per annum Up to 10% of unselected women with breast cancer are positive for BRCA1/2 (1,2) 20% of newly diagnosed breast cancer patients a
Slide 24: Pipeline - Aplidin
Pipeline - Aplidin® First in class drug with a novel mechanism of action Aplidium albicans PLITIDEPSIN MECHANISM OF ACTION Targets eEF1A2 Proto-oncogene over-expressed in different tumor types e.g. multiple myeloma eEF1A2 Non-canonical functions of eEF1A2: Regulation of oxidative stress (e.g
Slide 25: Pipeline – Aplidin
Pipeline – Aplidin® First in class drug with a novel mechanism of action CLINICAL PROGRAM/ REGISTRATION INDICATION PHASE I PHASE II PHASE III APPLICATION MARKET PARTNERS Aplidin® R/R multiple myeloma 4th line; Aplidin® + Dexameth EU/others R/R T-cell lymphoma Single agent (Pivotal) R/R multiple myel
Slide 26: Aplidin - ADMYRE Trial Design
Aplidin® - ADMYRE TRIAL DESIGN Phase III in Relapsed / Refractory Multiple Myeloma Phase III MM 250 Patients After 3, but no more than 6 lines of chemotherapy Randomization 2:1 Arm A: Arm B: Aplidin® + Dexamethasone Dexamethasone only (n=167) (n=83) IDMC positive recommendation (Dec 2012) RR ≥ 30%
Slide 27: Yondelis - Commercial expansion worldwide
Yondelis® - Commercial expansion worldwide First marine-derived oncology drug in the market, validating strategy Marketed in over 80 countries for: Advanced or metastatic soft tissue sarcoma Relapsed platinum-sensitive ovarian cancer (with Doxil®/Caelyx®) Commercialized by PharmaMar in Europ
Slide 28: Yondelis - Commercial expansion worldwide
Yondelis® - Commercial expansion worldwide PHM territories • Western EU: PharmaMar subsidiaries • Scandinavia and Eastern Europe: Swedish Orphan Biovitrum • Greece, Cyprus and Balkans:Genesis Pharma Partner territories EEUU and rest of the word (exclud. EU) :Janssen Japan : Taiho 28
Slide 29: Group revenues and profitability
Group revenues and profitability 2015 record year total revenue Revenues EBITDA € millions € millions 25.7 194 178 35 23.8 200 161 164 20.4 5.7 19.3 30 180 31.8 3.8 28.4 4.9 5 25 160 22.8 23.5 140 20 67.3 120 66.5 15 28.9 61.8 26.2 64.7 23.7 100 22.8 10 80 5 60 94.6 79.1 82.3 0 40 72.4 -7.3 -6.3 -8.
Slide 30: Net debt and operating cash flows
Net debt and operating cash flows Funding R&D and paying down debt Net Debt Total Debt € millions € millions 100 86.4 160 79.5 140 64.6 120 54.9 53 46.9 100 50 55 80 29 41 45 60 40 83 62 53 65 20 47 0 0 2011 2012 2013 2014 2015 2011 2012 2013 2014 2015 Long debt Short debt Operating cash flow pays
Slide 31: Key Events
Key Events Transformative times for Pharma Mar Reverse merger Zeltia with PharmaMar (October 2015) Yondelis® approved in Japan for STS (September 2015) Yondelis® approved in the US for STS (October 2015) PM1183 interim safety analysis Phase III in platinum-resistant ovarian cancer (H1 2016)
Slide 32: For more information: www.pharmamar.com
For more information: www.pharmamar.com